CAI — Caris Life Sciences, Inc.

Summary of Caris Life Sciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $293 million for Q4 2025, up 125% year-over-year, driven by clinical profiling services.
• Clinical Profiling Revenue: $282 million, a 199% increase year-over-year.
• Pharma R&D Services Revenue: $10.8 million for Q4.
• Gross Margin: 75% on a GAAP basis, up from 54% in Q4 2024.
• Net Income: Positive GAAP net income of $82 million.
• Adjusted EBITDA: $106 million for Q4; $138 million for the full year.
• Free Cash Flow: Positive $39.7 million for Q4; $67 million for the full year.
• Cash on Hand: Exceeded $800 million, increasing by $43 million in the quarter.

2. Strategic Updates and Business Highlights

• Clinical Activity: Completed nearly 200,000 individual cases in 2025, with a molecular dataset now exceeding 1 million profiled cases.
• New Initiatives: Plans to launch a revolutionary Cancer Early Detection Test (Caris Detect) in Q2 2026, leveraging advanced whole genome sequencing.
• Commercial Expansion: New Chief Commercial Officer Bobby Hill is leading efforts to expand the sales force by 20-25%, enhancing programming and education to deepen relationships with oncologists.
• Product Pipeline: Progress on multiple products, including MI Cancer Seek and various MRD assays.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $1.0 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to 2025.
• Clinical Volume Growth: Anticipated therapy selection volume growth of approximately 20% year-over-year.
• ASP Projections: Tissue ASP expected to reach approximately $4,000 in Q1 and $4,200 for the full year; blood ASP projected to be $2,400 to $2,500.
• Operating Expenses: Expected GAAP operating expenses of $590 million to $595 million, reflecting a 19% to 20% increase primarily due to commercial expansion and R&D activities.

4. Bad News, Challenges, or Points of Concern

• Pharma Revenue Decline: Year-over-year decrease in pharma revenue, although management expects to build momentum with new partnerships.
• ASP Caution: Management is taking a cautious approach to ASP guidance, particularly for blood assays, due to fluctuations in payer responses.
• Market Competition: The competitive landscape remains challenging, particularly with emerging technologies and companies in the early detection space.

5. Notable Q&A Insights

• Volume Outlook: Management indicated a breakdown of growth expectations with tissue in the low teens and blood in the high 50s for Q1.
• Sales Force Expansion: The sales force is expected to grow from approximately 250 to 300, with productivity anticipated to ramp up in the second half of the year.
• MCED Test Launch: The launch of Caris Detect is contingent on the final readout of the ACHIEVE-1 study, which is expected to provide critical data for market entry.
• MRD Development: Ongoing data collection is necessary for MRD assays, with no specific timelines provided for updates.
• CapEx Plans: $60 million allocated for CapEx in 2026, primarily for early detection launch preparations and testing equipment.

This summary encapsulates the key points from the earnings call, highlighting Caris Life Sciences' strong financial performance, strategic initiatives, and forward-looking guidance while addressing potential challenges and insights from the Q&A session.